Loading...
•
Jun 30, 2022
Mirum Pharmaceuticals Q2 2022 Earnings Report
Reported financial results for the second quarter ended June 30, 2022 and provided a business update.
Key Takeaways
Mirum Pharmaceuticals reported net product sales revenue of LIVMARLI for the quarter ended June 30, 2022 was $17.5 million. The company reported a net loss of $26.9 million, or $0.84 net loss per share. As of June 30, 2022, Mirum had cash, cash equivalents, restricted cash equivalents and investments of $225.0 million.
Net product sales for LIVMARLI totaled $17.5 million in the second quarter of 2022.
Total operating expenses for the quarter ended June 30, 2022 were $48.9 million.
For the quarter ended June 30, 2022, Mirum reported a net loss of $26.9 million, or $0.84 net loss per share.
As of June 30, 2022, Mirum had cash, cash equivalents, restricted cash equivalents and investments of $225.0 million.
Forward Guidance
Mirum expects a strong finish to 2022 with topline MARCH PFIC Phase 3 data and anticipated EMA approval in Alagille syndrome by the end of the year.
Positive Outlook
- Potential approval of MAA for the treatment of cholestasis in patients with Alagille syndrome in the fourth quarter of 2022.
- Topline data evaluating more than 90 patients in the MARCH PFIC Phase 3 clinical trial in the fourth quarter of 2022.
- Topline data in the EMBARK Phase 2b clinical trial for biliary atresia in the second half of 2023.
- Interim analysis for the VISTAS Phase 2b clinical trial for primary sclerosing cholangitis in mid-2023.
- Interim analysis for the OHANA Phase 2b clinical trial for intrahepatic cholestasis of pregnancy in the first half of 2023.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...